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Abstract 
Viral hepatitis C is not only a major public health problem by its significant morbidity and mortality worldwide, 
but also a medical and economical burden. Over the last 5 years, numerous research laboratories have enabled 
the development of several direct acting anti-HCV molecules whose effectiveness is well established. Great 
progress has been made in particular in the field of therapy although the cost of these treatments is today the 
focus of discussions, dissemination of new antiviral treatments to direct action should be a priority for public 
powers to heal and reduce the complications of this disease, thus the line ministry has given permission to 
market a generic of sofosbuvir drugs at an affordable price, acceptable and 80 times cheaper than the princeps. 
The first part of this paper elucidates the news of new drugs available to treat HCV, in the second part 
economical study aspects of the different therapeutical strategies currently available in Morocco. Thus we will 
study impacts of economical consequences of the therapy used against chronic hepatitis C.  
Keywords: Sofosbuvir; hepatitis C; direct-acting antiviral; guideline and management of viral hepatitis C; 
therapeutic and economic study in morocco; sustained virological response 
 
1. Introduction 
Viral hepatitis C remains a public health problem with its high prevalence worldwide and risk of progression to 
cirrhosis and hepatocellular carcinoma. This disease is usually silent and asymptomatic for a long time (De 
Ledinghen 2002). Much of HCV carriers do not know their HIV status (Zou, et al. 2001). In Morocco, the 
prevalence of viral hepatitis C in the general population is 1.58% (Baha, et al. 2013). 20-30% of patients with 
chronic hepatitis C can evolve to liver cirrhosis after 20 years (Seeff 2002, Myers, et al. 2012). 
The treatment of chronic viral hepatitis C is changing every day, allowing a gradual improvement in the 
eradication rates of hepatitis C virus (HCV). Great therapeutic progress has been made. Historically, the duration 
of HCV treatment was 24 to 48 weeks with uncertain effectiveness and cure rates ranged from 40% to 50% of 
cases, with treatment intolerance and a lot of side effects. From 2011, new antiviral drugs on the market permit 
many advantages:  
 cure rate of viral hepatitis C which exceeds 90% 
 ease of administration, 
 the treatment duration was reduced to 24 see 12 weeks using new protocols, 
 Tolerance of antiviral drugs with fewer side effects. 
Scientific research advances have enabled the arrival of new drugs and new drug combinations, to 
improve the effectiveness and even manage to eradicate HCV in 90% of patients (Liver 2014, Pawlotsky 
2014) .The main drawback of these new drugs is the high cost that far exceeds the cost of research and 
development. At present, the use of most of these new treatments should be based on the severity of liver disease 
evaluated either by liver biopsy (LB) or by non-invasive methods such as fibrotest (Sogni). Although the 
therapeutic strategies used as a therapeutic arsenal to eradicate the infection by the hepatitis virus is proved by 
several studies, the economic consequences of the choice of treatment remains to be studied. 
 
2. Objectives of treatments 
The primary goal is to quickly and sustainably eradicate virus without possibility of relapse (Marcellin, et al. 
2007). 
The secondary objectives are to: 
 protect the liver,  
 decrease of fibrosis progresses (Duchatelle, et al. 1998, Poynard, et al. 2002)  
 allow regression and even decompensate histological lesions of fibrosis including 
cirrhosis and HCC (Cardoso, et al. 2010) 
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 Improve patient’s quality of life. 
 
3. Therapeutic target 
Each stage of the HCV life cycle including the involvement of an enzyme (receptor binding, endocytosis, 
translation, cleavage of the polyprotein, viral replication...) is a potential target for developing new antiviral 
product. Currently there are several websites inhibitions (Schaefer and Chung 2012): 
 Protease inhibitors, 
 Inhibitors nucleoside or nucleotide polymerase, 
 Inhibitors non nuclesosidic polymerase, 
 Other anti-NS5A inhibitors 
 
4. Classification of viral drugs 
There are three main antiviral HCV classes: 
 Antivirals targeting the viral host,  
 Direct acting antivirals (DAA), 
 Active substances targeting host proteins are also under consideration (if are 
cyclophilin inhibitors). 
 
4.1. Antivirals targeting host and virus 
4.1.1. Pegylated Interferon alpha (Pegasys and Viraferonpeg) 
The interferon was identified in 1957 by Isaacs and Lindenmann for its antiviral properties. Interferons are 
proteins belonging to the cytokines family which are secreted by endogenous cells of the immune system 
(Pawlotsky 2002). Pegylated interferon is a long-acting form of interferon which is administered by 
subcutaneous injection at a rate of one per week, initially used only in the treatment of HCV and later in 
association with ribavirin. The administration of interferon is associated with several side effects (flue-like 
symptoms: muscle pain, tiredness, headache, convulsions, dizziness, thinning hair, depression) (Liu 2005, Bhatti 
and Berenson 2007)  
4.1.2. Ribavirin (Copegus®, Rebetol® Ribavir®) 
Ribavirin nucleoside of guanine shows antiviral properties in vitro toward many viruses. Its mode of action 
remains partly unsolved but several mechanisms seem to be involved with a dual action both directly on the 
virus (AAD) and indirectly on the host. Apparently ribavirin inhibits the replication of the viral RNA by 
inhibiting RNA polymerase (NS5B). Ribavirin is administered orally twice daily at 12 hours apart. It is marketed 
in three dosage forms (capsules, tablets 200 mg and oral solution dosed at 40mg/ml). Ribavirin dosage depends 
on viral genotype and the patient's weight; it is between 800 mg and 1200 mg/day (Bhatti and Berenson 2007, 
Husson 2008).  
 
4.2. Direct antiviral agents hepatitis C  
4.2.1. Protease inhibitors 
NS3 protease has an RNA helicase activity. It is made functional by the Association to the NS4A cofactor. It 
cleaves other non-structural proteins (NS4B, NS5A and NS5B). Inhibitors of HCV protease have better antiviral 
potency in preventing the release of functional non-structural proteins, they have a pan-genotypic activity except 
for genotype 3 (Loustaud-Ratti, et al. 2009). 
 NS3-4A protease inhibitors: first generation of the first wave, Telaprevir (Janssen) and Boceprevir 
(Merck) These protease inhibitors can be used in combination with or without Pegylated interferon and even in 
combinations without ribavirin(Bacon, et al. 2011, Jacobson, et al. 2011, Poordad, et al. 2011, Zeuzem, et al. 
2011). 
 NS3-4A first generation protease Inhibitors are the second wave of new drugs approved in 2014/2015 in 
the US by the FDA or by HAS in France. This is the case of Simeprevir (Janssen), and Faldaprevir (Boehringer 
Ingelheim, Germany). These molecules acting on genotypes 1, 2 and 4 but not on the genotype 3 (Lahser, et al. 
2012). 
 Other protease inhibitors are in development, these molecules are called (2nd generation protease 
inhibitors), they have similar activity to Telaprevir and boceprevir for example: Danoprevir, Soveprevir, 
Vedroprevir... 
4.2.2. NS5B Polymerase inhibitors of HCV 
The NS5B RNA-dependent RNA polymerase ensures viral replication, polymerase inhibitors that interfere with 
HCV replication. These products are two different mechanisms: 
 Nucleos(t)ide inhibitors, 
 Non-nucleos(t)ide inhibitors 
The activity of these products is equivalent to all genotypes; they have a high genetic barrier to resistance. 
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The nucleos(t)ides act by competitive inhibition at the active site of the enzyme; they mimic the natural substrate 
of the polymerase, making it ineffective. As the active site of the enzyme is well preserved, these molecules may 
have similar efficacy on all genotypes. These nucleoside or nucleotide NS5B polymerase inhibitors are currently 
represented by two molecules: 
 a nucleotide inhibitor, Sofosbuvir, which has a strong pan-genotypic antiviral activity 
and a high genetic barrier resistance (Huang, et al. 2010, Lawitz, et al. 2014, Lawitz, et al. 
2013, Osinusi, et al. 2013). 
  a nucleosidic inhibitor, the Mericitabine, which has antiviral activity. 
Non-nucleoside inhibitors that act by direct interaction with the active site or by binding to the allosteric site thus 
preventing the initiation process: non-nucleotide NS5B polymerase inhibitor: Dasabuvir and Lomibuvir ... 
 
5. Combination and therapeutic schemes 
For decades, the standard treatment for chronic hepatitis C is based on pegylated interferon and ribavirin taken 
which enabled eradication of 20% to 50% of HCV virus (Asselah 2014).  
In 2011, the placing on the market of first generation protease inhibitors (Telaprevir and Boceprevir) 
are used as a combination therapy with pegylated interferon and ribavirin. This protocol improved the cure rate 
over 70% (Jacobson, et al. 2011).  
From 2014, a new generation of direct acting antivirals is providing doctors and patients that act on all 
genotypes, and are used with single regimens administered orally, short, without adverse effects 
 
5.1. Before 2011 dual therapy: 
Combination therapy based on pegylated interferon and ribavirin is the standard treatment in the management of 
HCV. 
5.1.1. Pegylated alpha Interferon (PEG-IFNa) 
Administration of the pegylated interferon alpha is administrated by one injection once a week subcutaneously 
for a period of 6 months with genotype 2, 3 and 5 and 12 months if genotype 1, 4, 6. The pegylated interferon 
alpha has a side effect: flu-like illness, tiredness, weight loss, psychiatric disorders (depression, anxiety ...), 
neutropenia, thyroid dysfunction and skin reaction at the injection site (Duclos-Vallée and Samuel 2000). 
5.1.2. Ribavirin 
Ribavirin is taken orally 2-3 tablets 2 times/day with meals for a period of 6 months for genotypes 2, 3, 5 and 12 
months for genotypes 1, 4 and 6. Ribavirin has many side effects: anaemia, heart disorders (Duclos-Vallée and 
Samuel 2000). 
5.1.3. Drawback combination of this therapy 
Combination therapy is associated with many drawbacks (Pariente, et al. 2003): 
 tolerance and adherence, resulting discontinuation of treatment in 10 to 30% of cases 
during the first 6 months; 
 the duration of treatment,  
 Decrease of efficacy: a sustained virological response (SVR) barely equal 55% 
depending on the genotypes (Manns, et al. 2001). 
 
5.2. From 2011: Triple therapy 
With the appearance of two protease inhibitors first generation: Boceprevir/Telaprevir inhibitors of the serine 
protease NS3 of HCV. These two molecules are used in combination with pegylated interferon and ribavirin; 
allow us a therapeutic advantage of 25 to 30% compared to the combination therapy. In addition to the 
possibility of reducing the 24-week treatment period in almost half of patients. The protease inhibitors have 
drawbacks as: dermatologic complications, anaemia, these side effects are amplified by the concomitant use of 
ribavirin, and they have many drug interactions (McHutchison, et al. 2009). 
 
5.3. From 2014: the revolution of the management of HCV 
The new DAAs drugs are used in combination with pegylated interferon and ribavirin. Treatment with interferon 
is characterized by the risk of side effects, prompting experts AFEF recommend abandoning the use of interferon. 
Several regimens are proposed in the treatment of HCV by international consensus conferences and the learned 
society; these guidelines are shown in Table 1. 
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Table 1: Recommended treatment regimens (May 2014) for the different genotypes by the ANRS (National 
Agency of INSERM) and AFEF (French Association for the Study of the Liver). 
Molecules genotypes References 
SOFOSBUVIR+PEGYLATED 
INTERFERON+RIBAVIRINE 
Pangenotype 
(Lawitz, et al. 2013, Chazouillères , 
Lawitz, et al. 2013) 
SOFOSBUVIR+RIBAVIRINE Pangenotype (Gane, et al. 2013, Jacobson, et al. 2013, 
Osinusi, et al. 2013) 
SOFOSBUVIR+DACLATASVIR Genotypes 1 et 3 (Lawitz, et al. 2014, Pol, et al. 2015, 
Dhaliwal and Nampoothiri 2014) 
SOFOSBUVIR+SIMÉPRÉVIR Genotype 1b (Chazouillères , Dieterich, et al. 2014, 
Kwo, et al. 2015) 
The guidelines of AFEF (French association of the liver study) for HCV treatment recommends the us 
combination with direct-acting antiviral (DAA) drugs, this protocol without pegylated interferon has a 
consequences (Chazouillères):  
 SVR surrounding 100% 
 increase the antiviral efficacy without increasing toxicity, 
 lack of cross-resistance, 
 Lack of drug interactions and toxicities direct cross. 
 
 
6. Economic study of algorithms in Morocco 
Pharmaco-economic evaluation of drugs used in the treatment of chronic HCV is hampered by lack of 
information on the extent of health criteria and cost data. Our study aimed to evaluate the economic cost of the 
treatment of chronic HCV and proceeded to a comparison of therapeutic strategies in effect. So we made the 
main purpose of this study is to make a pharmaco-economic comparison of four strategies recommended in 
Morocco: 
 Dual therapy: pegylated interferon alpha and ribavirin, 
 Triple therapy with protease inhibitor: Boceprevir), pegylated interferon alpha and ribavirin. 
 Triple therapy with sofosbuvir: sofosbuvir) coupled with pegylated interferon and ribavirine  
 Sofosbuvir combined with  Daclatasvir 
Initially, the cost of medical taken direct expenses and current treatment costs were determined. Indeed 
we compare the costs of different protocols in Morocco. Finally we evaluated the economic impact on the 
treatment of HCV. 
 
6.1. Inventory of anti HCV medications marketed in Morocco 
Since the discovery of HCV in 1989, treatment algorithms have followed the scientific research progress and 
allowed a better management of this disease; Table 2 gives the state of play for anti-HCV treatment. 
Table 2: list of drugs treatment of chronic hepatitis C marked in Morocco. 
NAME OF 
DRUG 
DCI FORM DOSAGE PRESENTATION PRICE 
MAD 
LABORATORY 
COPEGUS Ribavirine Oral 1000 mg/day if 
<75 kg Weigh 
1200 mg/j if 
weigh ≥75 kg 
168 Cp 200 mg 5510 ROCHE 
REBETOL Ribavirine Oral 140 capsule 200 
mg 
 MSD 
RIBAVIR Ribavirine Oral 84 capsule 200 mg 900 Pharma5 
PEGASYS Peg-
Interferon 
α 2a 
Injection 180µg/week Syringe 135 µg 
Syringe180 µg 
2231 
2577 
ROCHE 
VIRAFERON Peg-
Interferon 
α 2b 
Injection 1,5µg/kg/week Syringe 100 µg 
Syringe 120 µg 
2028 
2497 
MSD 
VICTRELIS 
200 mg 
Boceprevir Oral 800mg 3x/day Box of 336 pills 25590 MSD 
SSB400 Sofosbuvir Oral 400mg/day 30 pills 400 mg 3000 Pharma5 
Dakasvir Daclatasvir Oral 60mg/day 28 pills 60 mg 1549 Pharma5 
 
6.2. Cost of current treatment algorithms in Morocco 
The current state highlighted the following therapeutic strategies: 
 Protocol 1: combination therapy is recommended standard treatment before 2011: Pegylated interferon 
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alpha and ribavirin. 
 Protocol 2: This is a recommended triple therapy since 2011 which is the subject of a combination of 
anti-protease (boceprevir), the pegylated interferon alpha and ribavirin. 
 Protocol 3: A triple therapy is used in Morocco from December 2105 that alternatively the anti-
polymerase (sofosbuvir) coupled with pegylated interferon and ribavirin. 
 Protocol 4: combination therapy is recommended from February 2016 that uses the association: 
sofosbuvir and Daclatasvir. 
Table 3: Average Cost therapeutic strategies recommended in Morocco 
Release date Protocol Duration of 
treatment 
Average 
cost (MAD) 
Efficiency: 
(RVS) 
Major side 
effects 
Before 2011 protocol 1 : 
Peginterferon alpha-2a/b 
+ ribavirine 
12weeks 35883,00 20 à 50% 
(Fried, et al. 
2002, Davis, 
et al. 2003, 
McHutchison, 
et al. 1998) 
Asthenia,     flu-
like symptoms.... 
(GOURNAY and 
RICHOU 2008, 
Sparsa, et al. 
2000) 
24 weeks 71766,00 
48 weeks 94860,00 
After  2011 protocol  2 : 
Peginterferon alpha-2a/b 
+ Ribavirine+Boceprevir 
28 weeks 262479,00 50 à 70 % 
(Bacon, et al. 
2011, 
McHutchison, 
et al. 2009) 
Drug eruption, 
anemia.... 
(McHutchison, et 
al. 2009) 
48 weeks 449956,00 
December 
2015 
Protocol  3 : 
Peginterferon Alpha-
2a/b + Ribavirine + 
sofosbuvir 
12 weeks 44883,00 About 90% 
(Lawitz, et al. 
2015) 
Are those of 
interferon and 
ribavirine 
(Negro) 
February 
2016 
Protocol 4 : sofosbuvir + 
daclatasvir 
12 weeks 13500,00 More than 
95% 
(Negro , 
Hezode, et al. 
2015) 
 
Average cost of care for chronic viral hepatitis C due to HCV genotype 1-6 by: 
 Protocol 1 is considered a standard treatment using interferon Pegylated and ribavirin, this 
algorithm recommended for adult’s naive treatment with compensated liver disease not previously 
treated. the cost for treatment ranges between 24,336.00 to 189,720.00 MAD ((1US$=9 MAD) This 
variation in treatment costs is mainly due to the different doses, depending on the weight of patient, 
depending on genotype, depending on variety of the price marketed drugs. 
 Protocol 2, this therapeutic strategy (combination pegylated interferon, ribavirin and 
boceprevir) is considered a second-line treatment since it comes after failure of first treatment with 
ribavirin and pegylated interferon. According to Table 3, the cost is between 235,536.00 and 496,152.00 
MAD. This cost difference is mainly due to the variation of doses used according to the weight of the 
patients and the duration of treatment.  
 Protocol 3, this protocol use the combination of pegylated interferon, ribavirin and sofosbuvir, 
in that case the average cost is 44883,00 MAD for 12 week treatment. 
 Finally the average cost of Protocol 4 (using sofosbuvir and Daclatasvir) is 13500,00 MAD  
for a 12 week treatment. 
 
6.3. Discussion study pharmaco therapeutic economy 
A reading of Table 3 we see that protocols 3 (combining pegylated interferon, ribavirin and sofosbuvir) and 
protocols 4 (associating sofosbuvir and Daclatasvir) are: 
 In term of economic are less expensive than the other two combinations namely combination 
therapy (interferon and ribavirin) and triple therapy (boceprevir, interferon and ribavirin) 
 In term of efficacy these combinations allow a sustained virologic response (SVR) excess of 
90%. the cost efficiency (SVR)  ratio varies from therapeutic strategy to another, if the SVR for 
combination therapy and triple  therapy with anti protease inhibitors  is from 20 to 50% and from 50 to 
70% respectively, this SVR exceeds 90% for therapy with polymerase ( protocols 3 and 4) (Osinusi, et al. 
2013, Gane, et al. 2013). 
 In term of duration, protocols 3 and 4 allowed the passage of a complex treatment for a long 
period which exceeds 48 weeks to a single treatment in only 12 weeks (Lawitz, et al. 2013, Zeuzem, et al. 
2014).  
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 In term of tolerance, protocols 3 and 4 are therapies less side effects months and  more 
tolerated (Hanslik and Ouzan , Naqvi, et al. 2015) 
It can be concluded that treatments by sofosbuvir revolutionized the treatment of HCV, this treatment is: 
cheaper than other protocols, SVR increased until than 95%, better tolerated and more efficient and more 
economical . 
In Morocco, access to care is very depending on medical coverage or not, owning a mutual or sickness 
insurance, economic management is evaluated on several points of views: 
 CNOPS perspective 
 CNSS perspective 
 RAMED perspective 
 Private insurance perspective 
 Patient's perspective 
 Since 2012, management of hepatitis C This is a national priority by Ministry of Health, which 
launched the program of access to care for viral hepatitis C by mobilizing a budget of 65 million DH for the 
purchase of dual therapy: pegylated interferon and Ribavirine. In December 2015, the authorization for the 
market by the Ministry of SSB400 * (sofosbuvir) and dakasvir* (Daclatasvir) by a Moroccan laboratory at a 
price of 3000 MAD box of 28 tablets is 9000 MAD 3 months of treatment for sofosbuvir and at a price of 1549 
DH box of 28 tablets is 4647 MAD 3 months of treatment, for comparison, the cost of that course of 12 weeks is 
more than 451,000 MAD in France and 800 000 MAD to the USA. This will allow a saving of several million 
DH payers (health insurance or local authority Patient Care Provider: hospital, clinic or doctors, and the 
Company), especially as the new recommendations of the AFEF suggest not more use interferon because of the 
side effects except in exceptional cases. 
 
7. Conclusion 
The first drugs used 25 years ago in order to treat hepatitis C were  interferon administrated every day, few years 
after, ribavirin was used which is an oral antiviral to increase efficiency of interferon. This combination therapy: 
interferon, ribavirin was the standard of care in the treatment of hepatitis C with a sustained virologic response of 
20 to 70% depending on the genotype and especially with many side effects (Laguno, et al. 2004, Siebert, et al. 
2003, Fried, et al. 2002). 
In 2011, two protease inhibitors have obtained marketing authorization: Telaprevir and boceprevir, the 
both molecules used in combination with pegylated interferon and ribavirin, this combination therapy have 
increased SVR up to 25%, but this effectiveness is confronted with the appearance of several side effects and a 
lot of drug interactions. 
Since 2014, the development of new molecules by different research centers around the world causes 
the change of the paradigm of HVC, with the emergence of new direct-acting antivirals (DAA), a great advance 
in managing HCV has been crossed (Chazouillères). 
We start with a complex treatment, heavy and lasting at least 48 weeks with significant side effects and 
a sustained virological response that hardly exceeds 50%, to a regimen single oral, short, well tolerated with no 
adverse events and especially with RVS now exceeding 90% in just 12 weeks (Chazouillères). 
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